Stay updated on Pembrolizumab in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab in Lymphoma Clinical Trial page
- Check7 days agoChange DetectedAdded Revision: v3.3.4 and removed Revision: v3.3.3 in the Study Documents section. This appears to be a metadata/version update to the protocol/document rather than a change to trial design or results; to avoid alerts for small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedAdded a Locations section listing Washington as a study site (Seattle, WA) and removed the prior Washington Locations label and the HHS Vulnerability Disclosure link; page revision updated to v3.3.3.SummaryDifference0.2%

- Check50 days agoChange DetectedThe header now displays Revision: v3.3.2, replacing Revision: v3.3.1. No substantive study information is changed.SummaryDifference0.0%

- Check57 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.1 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check65 days agoChange DetectedThe funding lapse notice about government funding and NIH operating status was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check79 days agoChange DetectedAdministrative updates are present, including a new last update date and posted results, while the core study design, arms, and eligibility remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Lymphoma Clinical Trial page.